Increased Expression of Survivin in Hepatoblastoma after Chemotherapy

 

 Buy Article Permissions and Reprints

Abstract

Background Survivin, an inhibitor of apoptosis, has been reported to be associated with a worse prognosis in some malignancies. However, its expression in hepatoblastoma (HB) remains to be elucidated. We assessed the survivin expression in HB specimens collected before and after chemotherapy to elucidate the impact of survivin on the outcome of HB therapy.

Methods HB specimens were collected before and after 2 to 4 cycles of cisplatin-based chemotherapy from 16 patients. The survivin expression level was assessed by immunohistochemical staining and real-time polymerase chain reaction.

Results Out of 16, 12 HB sections collected before chemotherapy were positive for survivin as determined by immunohistochemical staining. The intensity of survivin expression was found to significantly increase after chemotherapy. Surprisingly, all of the HB specimens obtained after chemotherapy were positive for survivin. The expression of survivin messenger ribonucleic acid from a human HB cell line, Huh-6 was significantly higher when the cells were cultured with cis-diamminedichloroplatinum(II) than when the cells were cultured without the drug.

Conclusion Our results indicate that most of the primary HB tissue specimens express survivin, and its expression increased after chemotherapy, thus suggesting that survivin may concern with the survival of tumor cells, therefore be a candidate for the target of the treatment of HB.

• References

• 1 Perilongo G, Shafford E, Plaschkes J. Liver Tumour Study Group of the International Society of Paediatric Oncology. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000; 1: 94-100
  CrossrefPubMedGoogle Scholar
• 2 Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42 (13) 2115-2123
  CrossrefPubMedGoogle Scholar
• 3 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3 (8) 917-921
  CrossrefPubMedGoogle Scholar
• 4 Tamm I, Wang Y, Sausville E , et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58 (23) 5315-5320
  PubMedGoogle Scholar
• 5 Ito R, Asami S, Motohashi S , et al. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 2005; 28 (4) 565-568
  CrossrefPubMedGoogle Scholar
• 6 Kappler M, Köhler T, Kampf C , et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001; 95 (6) 360-363
  CrossrefPubMedGoogle Scholar
• 7 Hishiki T, Matsunaga T, Sasaki F , et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 2011; 27 (1) 1-8
  CrossrefPubMedGoogle Scholar
• 8 Sasaki F, Matsunaga T, Iwafuchi M , et al; (Japanese Study Group for Pediatric Liver Tumor).. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002; 37 (6) 851-856
  CrossrefPubMedGoogle Scholar
• 9 Wang Z, Xie Y, Wang H. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 2005; 4 (7) 716-719
  CrossrefPubMedGoogle Scholar
• 10 Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22 (53) 8581-8589
  CrossrefPubMedGoogle Scholar
• 11 Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14 (16) 5000-5005
  CrossrefPubMedGoogle Scholar
• 12 Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8 (1) 61-70
  CrossrefPubMedGoogle Scholar
• 13 Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol 2011; 82 (9) 1066-1072
  CrossrefPubMedGoogle Scholar
• 14 Tsuruma T, Hata F, Torigoe T , et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2 (1) 19
  CrossrefPubMedGoogle Scholar
• 15 Burris III HA, Moore MJ, Andersen J , et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (6) 2403-2413
  CrossrefPubMedGoogle Scholar
• 16 Guo Q, Chen Y, Zhang B, Kang M, Xie Q, Wu Y. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 2009; 77 (11) 1674-1683
  CrossrefPubMedGoogle Scholar
• 17 Tsuruma T, Hata F, Torigoe T , et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2 (1) 19
  CrossrefPubMedGoogle Scholar